17 active not recruiting. 17 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Active not recruiting 17 |
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 3 | 2 | Active not recruiting 2 |
Follow Abnormalities, Multiple: new trials by email Literature Review of Abnormalities, Multiple trials Research Report on Abnormalities, Multiple
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) VX-407 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 26 | 2025-11-19 | 2026-09-21 |
| A Study of Setmelanotide in Patients With Prader-Willi Syndrome Setmelanotide - Prader-Willi Syndrome, Obesity | Phase 2 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 18 | 2025-03-04 | 2026-11-13 |
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Active not recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2026-11-18 |
| A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718 - Hypothalamic Obesity, Prader-Willi Syndrome | Phase 1 / Phase 2 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 111 | 2024-03-05 | 2026-10-09 |
| Study of Tamibarotene in Patients With ADPKD Tamibarotene, Placebo - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Active not recruiting | Rege Nephro Co., Ltd. | 70 | 2023-12-22 | 2025-04-04 |
| Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome Atomoxetine and Oxybutynin (ato-oxy) - Obstructive Sleep Apnea, Down Syndrome | Phase 2 | Active not recruiting | University of Arizona | 36 | 2023-09-29 | 2026-04-07 |
| AMX0035 in Adult Patients With Wolfram Syndrome AMX0035 - Wolfram Syndrome | Phase 2 | Active not recruiting | Amylyx Pharmaceuticals Inc. | 12 | 2023-03-03 | 2026-04-14 |
| Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease Empagliflozin, Placebo - Polycystic Kidney, Autosomal Dominant | Phase 2 | Active not recruiting | University of Colorado, Denver | 50 | 2022-11-18 | 2026-05-01 |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| MK-7075 (Miransertib) in Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 2 | Active not recruiting | National Human Genome Research Institute (NHGRI) | 38 | 2022-05-20 | 2026-07-17 |
| HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome ION582 - Angelman Syndrome | Phase 1 / Phase 2 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 71 | 2021-12-22 | 2026-11-17 |
| A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) Belzutifan - VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 50 | 2018-05-02 | 2026-04-13 |
| ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 Daunorubicin, Prednisolone, Vincristine - Down Syndrome, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | National Hospital Organization Nagoya Medical Center | 60 | 2017-04-18 | 2026-05-11 |
| MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen - Mucopolysaccharidosis Disorders, Hurler Syndrome | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 149 | 2014-07-10 | 2026-11-03 |
| A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B Blood draw for the laboratory assessment - Usher's Syndrome | Phase 2 | Active not recruiting | Sanofi | 9 | 2013-09-12 | 2026-01-13 |
Polycystic Kidney, Autosomal Dominant (4) · Usher Syndromes (3) · Down Syndrome (2) · Obesity (2) · Prader-Willi Syndrome (2) · Retinitis Pigmentosa (2) · Alpha-Methylacyl-CoA Racemase Deficiency (1) · Angelman Syndrome (1) · Aspartylglucosaminuria (1) · Eye Abnormalities (1) · Eye Diseases, Hereditary (1) · Fucosidosis (1) · Hereditary Diffuse Leukoencephalopathy with Spheroids (1) · Hyperphagia (1) · Leukodystrophy, Globoid Cell (1)
Congenital Abnormalities (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (17) · Genetic Diseases, Inborn (16) · Nervous System Diseases (11) · Neurologic Manifestations (9) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Urogenital Diseases (7) · Kidney Diseases (6) · Urologic Diseases (6) · Chromosome Disorders (5) · Ciliopathies (5) · Intellectual Disability (5)
4-phenylbutyric acid (1) · Atomoxetine Hydrochloride (1) · Blood Specimen Collection (1) · Cyclophosphamide (1) · Cytarabine (1) · Daunorubicin (1) · Epirubicin (1) · Hydrocortisone (1) · Mercaptopurine (1) · Methotrexate (1) · Miransertib (1) · Prednisolone (1) · Regimen B (1) · Stem Cell Transplantation (1) · Vincristine (1)
Rhythm Pharmaceuticals, Inc. (2) · AAVantgarde Bio Srl (1) · Amylyx Pharmaceuticals Inc. (1) · Camurus AB (1) · Ionis Pharmaceuticals, Inc. (1) · Laboratoires Thea (1) · Masonic Cancer Center, University of Minnesota (1) · National Hospital Organization Nagoya Medical Center (1) · National Human Genome Research Institute (NHGRI) (1) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Quoin Pharmaceuticals (1) · Rege Nephro Co., Ltd. (1) · Sanofi (1) · University of Arizona (1) · University of Colorado, Denver (1)
United States (14) · France (5) · United Kingdom (5) · Belgium (3) · Germany (3) · Italy (3) · Netherlands (3) · Canada (2) · Denmark (2) · Japan (2) · Australia (1) · Brazil (1) · Hong Kong (1) · Israel (1) · Malaysia (1)
Allen Yeoh, MBBS (1) · Camille Bedrosian, MD (1) · David Meeker (1) · David Meeker, MD (1) · Joost Drenth, MD (1) · Leslie G Biesecker, M.D. (1) · Michel B Chonchol, MD (1) · Paul Orchard, M.D. (1) · Tony Andrasfay (1)
PMID 39356039, PMID 34818478, PMID 38010035, PMID 39284337, PMID 40228516, PMID 40339601, PMID 40377984, PMID 41385299, PMID 42224880
2018 (1), 2023 (1), R01DK131755 (1), R33HL151254 (1)